| Literature DB >> 32917038 |
Olga Redina1, Vladimir Babenko1,2, Dmitry Smagin1, Irina Kovalenko1, Anna Galyamina1, Vadim Efimov1,2, Natalia Kudryavtseva1.
Abstract
Daily agonistic interactions of mice are an effective experimental approach to elucidate the molecular mechanisms underlying the excitation of the brain neurons and the formation of alternative social behavior patterns. An RNA-Seq analysis was used to compare the ventral tegmental area (VTA) transcriptome profiles for three groups of male C57BL/6J mice: winners, a group of chronically winning mice, losers, a group of chronically defeated mice, and controls. The data obtained show that both winners and defeated mice experience stress, which however, has a more drastic effect on defeated animals causing more significant changes in the levels of gene transcription. Four genes (Nrgn, Ercc2, Otx2, and Six3) changed their VTA expression profiles in opposite directions in winners and defeated mice. It was first shown that Nrgn (neurogranin) expression was highly correlated with the expression of the genes involved in dopamine synthesis and transport (Th, Ddc, Slc6a3, and Drd2) in the VTA of defeated mice but not in winners. The obtained network of 31 coregulated genes, encoding proteins associated with nervous system development (including 24 genes associated with the generation of neurons), may be potentially useful for studying their role in the VTA dopaminergic neurons maturation under the influence of social stress.Entities:
Keywords: RNA-Seq; chronically defeated mice (losers); chronically winning mice (winners); daily agonistic interactions; ventral tegmental area (VTA)
Mesh:
Substances:
Year: 2020 PMID: 32917038 PMCID: PMC7555283 DOI: 10.3390/ijms21186599
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Differentially Expressed Genes (DEGs) associated with the behavior/neurological phenotype.
| Gene Symbol | Locus | Expression in VTA (FPKM) | Log2 (Fold Change) Winners/Controls | q_Value | Definition | |
|---|---|---|---|---|---|---|
| Control Mice | Winners | |||||
| Winners vs. Control Mice | ||||||
|
| chr4:40720153-40757885 | 41.90 | 104.77 | 1.32 | 2.05 × 10−2 | DnaJ heat shock protein family (Hsp40) member A1 |
|
| chr7:19382024-19404104 | 53.42 | 8.72 | −2.62 | 2.05 × 10−2 | excision repair cross-complementing rodent repair deficiency, complementation group 2 |
|
| chr19:45232619-45235377 | 7.18 | 3.19 | −1.17 | 2.05 × 10−2 | ladybird homeobox homolog 1 (Drosophila) |
|
| chr8:115682935-115707940 | 9.66 | 5.98 | −0.69 | 3.58 × 10−2 | avian musculoaponeurotic fibrosarcoma oncogene homolog |
|
| chr14:54936101-54966607 | 1.47 | 59.90 | 5.35 | 2.05 × 10−2 | myosin, heavy polypeptide 6, cardiac muscle, alpha |
|
| chr11:95568820-95587698 | 3.55 | 2.01 | −0.82 | 2.05 × 10−2 | nerve growth factor receptor (TNFR superfamily, member 16) |
|
| chr5:101658055-101665361 | 5.01 | 2.79 | −0.85 | 3.58 × 10−2 | NK6 homeobox 1 |
|
| chr5:144545886-144557478 | 3.28 | 1.59 | −1.04 | 2.05 × 10−2 | neuronal pentraxin 2 |
|
| chr9:37544492-37552745 | 22.35 | 14.15 | −0.66 | 3.58 × 10−2 | neurogranin |
|
| chr7:45163920-45176328 | 10.74 | 20.59 | 0.94 | 2.05 × 10−2 | solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
|
| chr11:76998596-77032343 | 5.03 | 9.99 | 0.99 | 2.05 × 10−2 | solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
| chr2:181669836-181671640 | 9.60 | 5.15 | −0.90 | 2.05 × 10−2 | SRY (sex determining region Y)-box 18 |
|
| chr19:55741714-55933693 | 6.56 | 3.44 | −0.93 | 2.05 × 10−2 | transcription factor 7 like 2, T cell specific, HMG box |
|
| chr10:115078553-115185022 | 7.52 | 13.79 | 0.87 | 4.87 × 10−2 | tryptophan hydroxylase 2 |
|
| ||||||
|
|
|
|
|
|
|
|
|
| chr10:4266328-4359605 | 30.74 | 19.84 | −0.63 | 0.0159 | A kinase (PRKA) anchor protein (gravin) 12 |
|
| chr6:86736652-86793645 | 5.40 | 2.37 | −1.19 | 0.0063 | annexin A4 |
|
| chr7:128523582-128546979 | 21.99 | 9.86 | −1.16 | 0.0063 | BCL2-associated athanogene 3 |
|
| chr1:154390344-154884412 | 7.26 | 11.61 | 0.68 | 0.0275 | calcium channel, voltage-dependent, R type, alpha 1E subunit |
|
| chr7:114631477-114636357 | 23.97 | 5.14 | −2.22 | 0.0063 | calcitonin/calcitonin-related polypeptide, alpha |
|
| chr18:60925325-60988993 | 21.04 | 32.70 | 0.64 | 0.0275 | calcium/calmodulin-dependent protein kinase II alpha |
|
| chr17:29090985-29100722 | 5.82 | 3.43 | −0.76 | 0.0275 | cyclin-dependent kinase inhibitor 1A (P21) |
|
| chr7:143458338-143461074 | 5.59 | 3.08 | −0.86 | 0.0063 | cyclin-dependent kinase inhibitor 1C (P57) |
|
| chr3:130180797-130599886 | 3.25 | 5.24 | 0.69 | 0.0205 | collagen, type XXV, alpha 1 |
|
| chr14:31523083-31577383 | 2.14 | 0.78 | −1.45 | 0.0063 | collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
|
| chr5:114003734-114025676 | 5.17 | 2.55 | −1.02 | 0.0063 | D-amino acid oxidase |
|
| chr11:11814099-11898144 | 14.29 | 35.12 | 1.30 | 0.0063 | dopa decarboxylase |
|
| chr4:40720153-40757885 | 41.15 | 155.22 | 1.92 | 0.0063 | DnaJ heat shock protein family (Hsp40) member A1 |
|
| chr2:154559399-154569892 | 4.75 | 2.38 | −0.99 | 0.0063 | E2F transcription factor 1 |
|
| chr18:34861206-34864956 | 9.62 | 15.75 | 0.71 | 0.0115 | early growth response 1 |
|
| chr1:120602486-120607991 | 5.32 | 10.27 | 0.95 | 0.0063 | engrailed 1 |
|
| chr5:28165695-28172166 | 3.09 | 5.95 | 0.94 | 0.0063 | engrailed 2 |
|
| chr1:74881508-74885408 | 1.25 | 3.95 | 1.66 | 0.0063 | FEV (ETS oncogene family) |
|
| chr6:14901169-15442450 | 1.59 | 3.15 | 0.98 | 0.0063 | forkhead box P2 |
|
| chr11:42130920-42183066 | 45.26 | 77.94 | 0.78 | 0.0063 | gamma-aminobutyric acid (GABA) A receptor, subunit alpha 1 |
|
| chr11:42419746-42632694 | 19.55 | 29.08 | 0.57 | 0.0446 | gamma-aminobutyric acid (GABA) A receptor, subunit beta 2 |
|
| chr11:41909958-42000874 | 25.14 | 38.21 | 0.60 | 0.0159 | gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 |
|
| chr2:70489939-70602029 | 48.93 | 79.73 | 0.70 | 0.0063 | glutamate decarboxylase 1 |
|
| chr2:22622057-22694078 | 34.04 | 54.29 | 0.67 | 0.0243 | glutamic acid decarboxylase 2 |
|
| chr11:59175476-59183213 | 41.32 | 24.81 | −0.74 | 0.0115 | gap junction protein, gamma 2 |
|
| chr1:119415464-119422248 | 3.44 | 2.15 | −0.68 | 0.0374 | inhibin beta-B |
|
| chrX:141710996-141725254 | 1.76 | 3.33 | 0.92 | 0.0063 | insulin receptor substrate 4 |
|
| chr13:116298269-116309693 | 1.61 | 0.49 | −1.72 | 0.0063 | ISL1 transcription factor, LIM/homeodomain |
|
| chr19:45232619-45235377 | 7.04 | 0.71 | −3.32 | 0.0063 | ladybird homeobox homolog 1 (Drosophila) |
|
| chr8:115682935-115707940 | 9.48 | 5.55 | −0.77 | 0.0063 | avian musculoaponeurotic fibrosarcoma oncogene homolog |
|
| chr2:160363676-160367065 | 4.47 | 2.51 | −0.84 | 0.0063 | v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) |
|
| chr3:29951264-30013204 | 1.23 | 0.60 | −1.04 | 0.0063 | MDS1 and EVI1 complex locus |
|
| chr2:164948218-164955849 | 2.26 | 0.89 | −1.34 | 0.0063 | matrix metallopeptidase 9 |
|
| chr14:54936101-54966607 | 1.44 | 20.92 | 3.86 | 0.0243 | myosin, heavy polypeptide 6, cardiac muscle, alpha |
|
| chr11:4938562-5042794 | 287.73 | 119.70 | −1.27 | 0.0063 | neurofilament, heavy polypeptide |
|
| chr14:68082365-68092351 | 914.72 | 422.75 | −1.11 | 0.0063 | neurofilament, light polypeptide |
|
| chr14:68119465-68131373 | 690.57 | 269.10 | −1.36 | 0.0063 | neurofilament, medium polypeptide |
|
| chr11:98325416-98329645 | 2.92 | 1.59 | −0.88 | 0.0243 | neurogenic differentiation 2 |
|
| chr12:87097530-87102539 | 9.25 | 20.21 | 1.13 | 0.0063 | neuroglobin |
|
| chr11:95568820-95587698 | 3.48 | 1.91 | −0.86 | 0.0159 | nerve growth factor receptor (TNFR superfamily, member 16) |
|
| chr5:101658055-101665361 | 4.91 | 1.66 | −1.56 | 0.0063 | NK6 homeobox 1 |
|
| chr9:37544492-37552745 | 21.95 | 42.78 | 0.96 | 0.0063 | neurogranin |
|
| chr2:29193828-29253707 | 25.61 | 14.93 | −0.78 | 0.0275 | netrin G2 |
|
| chr14:48657676-48667644 | 0.73 | 2.03 | 1.49 | 0.0115 | orthodenticle homeobox 2 |
|
| chr4:139737093-139832968 | 0.45 | 1.64 | 1.85 | 0.0063 | paired box 7 |
|
| chr5:67094327-67099126 | 7.03 | 1.56 | −2.17 | 0.0063 | paired-like homeobox 2b |
|
| chr3:123446912-123506602 | 4.23 | 1.89 | −1.16 | 0.0063 | protease, serine 12 neurotrypsin (motopsin) |
|
| chr15:78191044-78206351 | 119.09 | 70.07 | −0.77 | 0.0063 | parvalbumin |
|
| chr2:65456990-65567519 | 3.86 | 6.64 | 0.78 | 0.0346 | sodium channel, voltage-gated, type III, alpha |
|
| chr10:89574019-89621249 | 0.90 | 2.12 | 1.24 | 0.0063 | solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8 |
|
| chr14:32407354-32466004 | 33.83 | 13.30 | −1.35 | 0.0063 | solute carrier family 18 (vesicular monoamine), member 3 |
|
| chr8:92960641-93001667 | 7.52 | 4.87 | −0.63 | 0.0346 | solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
|
| chr13:73536746-73578672 | 1.03 | 9.51 | 3.21 | 0.0063 | solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
| chr11:76998596-77032343 | 4.94 | 22.71 | 2.20 | 0.0063 | solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
| chr7:49909938-49963861 | 45.06 | 13.79 | −1.71 | 0.0063 | solute carrier family 6 (neurotransmitter transporter, glycine), member 5 |
|
| chr5:104435110-104441053 | 54.80 | 23.57 | −1.22 | 0.0063 | secreted phosphoprotein 1 |
|
| chr10:108497647-109010983 | 51.32 | 86.93 | 0.76 | 0.0063 | synaptotagmin I |
|
| chr12:86056580-86079159 | 6.99 | 4.46 | −0.65 | 0.0374 | transforming growth factor, beta 3 |
|
| chr7:142892670-142901960 | 10.93 | 21.96 | 1.01 | 0.0063 | tyrosine hydroxylase |
|
| chr10:115078553-115185022 | 7.40 | 26.97 | 1.87 | 0.0063 | tryptophan hydroxylase 2 |
|
| chr15:97854426-97908296 | 0.76 | 0.29 | −1.41 | 0.0115 | vitamin D receptor |
|
| chr5:137025191-137033857 | 119.24 | 78.61 | −0.60 | 0.0473 | VGF nerve growth factor inducible |
|
| chr12:116077725-116146261 | 1.83 | 0.39 | −2.24 | 0.0063 | vasoactive intestinal peptide receptor 2 |
|
| chr4:63414854-63496130 | 21.72 | 13.85 | −0.65 | 0.0275 | whirlin |
Genes associated with: #—abnormal emotion/affect behavior; ∆—abnormal aggression-related behavior; ¶—increased aggression towards mice; -abnormal fear/anxiety-related behavior; ©—abnormal depression-related behavior.
DEGs encoding transcription factors.
| Gene Symbol | Locus | Expression in VTA (FPKM) | log2 (Fold Change) Winners/Controls | q_Value | Definition | |
|---|---|---|---|---|---|---|
| Control Mice | Winners | |||||
| Winners vs. Control Mice | ||||||
|
| chr11:106780156-106818861 | 121.77 | 381.38 | 1.65 | 2.05 × 10−2 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 |
|
| chr7:19382024-19404104 | 53.42 | 8.72 | −2.62 | 2.05 × 10−2 | excision repair cross-complementing rodent repair deficiency, |
|
| chr2:31572650-31617590 | 11.21 | 60.26 | 2.43 | 2.05 × 10−2 | far upstream element (FUSE) binding protein 3 |
|
| chr19:45232619-45235377 | 7.18 | 3.19 | −1.17 | 2.05 × 10−2 | ladybird homeobox homolog 1 (Drosophila) |
|
| chr8:115682935-115707940 | 9.66 | 5.98 | −0.69 | 3.58 × 10−2 | avian musculoaponeurotic fibrosarcoma oncogene homolog |
|
| chr5:101658055-101665361 | 5.01 | 2.79 | −0.85 | 3.58 × 10−2 | NK6 homeobox 1 |
|
| chr1:180568937-180601389 | 12.93 | 102.04 | 2.98 | 2.05 × 10−2 | poly (ADP-ribose) polymerase family, member 1 |
|
| chr1:9960162-9967485 | 0.39 | 0.89 | 1.19 | 4.87 × 10−2 | transcription factor 24 |
|
| chr19:55741714-55933693 | 6.56 | 3.44 | −0.93 | 2.05 × 10−2 | transcription factor 7 like 2, T cell specific, HMG box |
|
| ||||||
|
|
|
|
|
|
|
|
|
| chr9:118921134-119044353 | 5.14 | 26.56 | 2.37 | 0.0063 | CTD (carboxy-terminal domain, RNA polymerase II, |
|
| chr2:154559399-154569892 | 4.75 | 2.38 | −0.99 | 0.0063 | E2F transcription factor 1 |
|
| chr18:34861206-34864956 | 9.62 | 15.75 | 0.71 | 0.0115 | early growth response 1 |
|
| chr1:120602486-120607991 | 5.32 | 10.27 | 0.95 | 0.0063 | engrailed 1 |
|
| chr5:28165695-28172166 | 3.09 | 5.95 | 0.94 | 0.0063 | engrailed 2 |
|
| chr1:74881508-74885408 | 1.25 | 3.95 | 1.66 | 0.0063 | FEV (ETS oncogene family) |
|
| chr6:14901169-15442450 | 1.59 | 3.15 | 0.98 | 0.0063 | forkhead box P2 |
|
| chr11:96323125-96354174 | 3.72 | 0.64 | −2.54 | 0.0063 | homeobox B2 |
|
| chr11:96323125-96354174 | 2.98 | 0.31 | −3.26 | 0.0063 | homeobox B3 |
|
| chr2:74710043-74765142 | 1.82 | 0.08 | −4.53 | 0.0115 | homeobox D3 |
|
| chr13:116298269-116309693 | 1.61 | 0.49 | −1.72 | 0.0063 | ISL1 transcription factor, LIM/homeodomain |
|
| chr19:45232619-45235377 | 7.04 | 0.71 | −3.32 | 0.0063 | ladybird homeobox homolog 1 (Drosophila) |
|
| chr8:115682935-115707940 | 9.48 | 5.55 | −0.77 | 0.0063 | avian musculoaponeurotic fibrosarcoma oncogene homolog |
|
| chr2:160363676-160367065 | 4.47 | 2.51 | −0.84 | 0.0063 | v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) |
|
| chr11:98325416-98329645 | 2.92 | 1.59 | −0.88 | 0.0243 | neurogenic differentiation 2 |
|
| chr5:101658055-101665361 | 4.91 | 1.66 | −1.56 | 0.0063 | NK6 homeobox 1 |
|
| chr11:21994763-22001651 | 0.62 | 2.50 | 2.01 | 0.0063 | orthodenticle homeobox 1 |
|
| chr14:48657676-48667644 | 0.73 | 2.03 | 1.49 | 0.01154 | orthodenticle homeobox 2 |
|
| chr19:44746709-44838266 | 8.34 | 3.02 | −1.47 | 0.0063 | paired box 2 |
|
| chr4:139737093-139832968 | 0.45 | 1.64 | 1.85 | 0.0063 | paired box 7 |
|
| chr5:67094327-67099126 | 7.03 | 1.56 | −2.17 | 0.0063 | paired-like homeobox 2b |
|
| chr3:94372793-94398274 | 2.97 | 1.40 | −1.08 | 0.0063 | RAR-related orphan receptor gamma |
|
| chr2:152081528-152095802 | 13.30 | 7.04 | −0.92 | 0.0063 | scratch family zinc finger 2 |
|
| chr9:99874105-99876170 | 0.74 | 2.21 | 1.57 | 0.0063 | SRY (sex determining region Y)-box 14 |
|
| chr4:115056425-115071758 | 2.45 | 4.25 | 0.80 | 0.0205 | T cell acute lymphocytic leukemia 1 |
|
| chr9:24720811-24774303 | 0.86 | 0.25 | −1.77 | 0.0063 | T-box 20 |
|
| chr15:97854426-97908296 | 0.76 | 0.29 | −1.41 | 0.0115 | vitamin D receptor |
|
| chr4:58943559-58962705 | 7.72 | 12.67 | 0.71 | 0.0063 | zinc finger with KRAB and SCAN domains 16 |
Genes associated with: *—behavior/neurological phenotype; #—abnormal emotion/affect behavior; ∆—abnormal aggression-related behavior; ¶—increased aggression towards mice; —abnormal fear/anxiety-related behavior.
Metabolic pathways most significantly altered in defeated mice compared to controls.
| Term | Count | Genes | |
|---|---|---|---|
| Nicotine addiction | 5 | 4.25 × 10−4 | |
| Axon guidance | 6 | 5.86 × 10−3 | |
| GABAergic synapse | 5 | 7.55 × 10−3 | |
| Amyotrophic lateral sclerosis (ALS) | 4 | 1.06 × 10−2 | |
| Amphetamine addiction | 4 | 2.20 × 10−2 | |
| Chronic myeloid leukemia | 4 | 2.65 × 10−2 | |
| Bladder cancer | 3 | 5.20 × 10−2 | |
| Transcriptional misregulation in cancer | 5 | 6.03 × 10−2 | |
| Retrograde endocannabinoid signaling | 4 | 6.48 × 10−2 | |
| Cocaine addiction | 3 | 7.12 × 10−2 | |
| Taurine and hypotaurine metabolism | 2 | 9.44 × 10−2 |
DEGs with changed expression both for the winners and losers (common DEGs).
| Gene Symbol | Log2 (Fold_Change) Winners/Controls | q_Value | Log2 (Fold_Change) Losers/Controls | q_Value | Definition |
|---|---|---|---|---|---|
|
| 1.14 | 2.05 × 10−2 | 1.38 | 6.29 × 10−3 | amyloid beta (A4) precursor protein-binding, family A, member 3 |
|
| −1.91 | 2.05 × 10−2 | −1.69 | 6.29 × 10−3 | bromodomain containing 3 |
|
| −5.45 | 2.05 × 10−2 | −5.43 | 6.29 × 10−3 | cyclin-dependent kinase 12 |
|
| 1.32 | 2.05 × 10−2 | 1.92 | 6.29 × 10−3 | DnaJ heat shock protein family (Hsp40) member A1 |
|
| −0.95 | 2.05 × 10−2 | −0.97 | 6.29 × 10−3 | EGF-like domain 7 |
|
| −4.17 | 2.05 × 10−2 | −3.96 | 6.29 × 10−3 | GCN1 general control of amino-acid synthesis 1-like 1 (yeast) |
|
| −0.90 | 2.05 × 10−2 | −1.43 | 6.29 × 10−3 | glial fibrillary acidic protein |
|
| −0.73 | 3.58 × 10−2 | −0.82 | 6.29 × 10−3 | predicted gene 13889 |
|
| −1.17 | 2.05 × 10−2 | −3.32 | 6.29 × 10−3 | ladybird homeobox homolog 1 (Drosophila) |
|
| −0.69 | 3.58 × 10−2 | −0.77 | 6.29 × 10−3 | avian musculoaponeurotic fibrosarcoma oncogene homolog |
|
| −0.64 | 4.87 × 10−2 | −0.79 | 6.29 × 10−3 | myosin, heavy polypeptide 14 |
|
| 5.35 | 2.05 × 10−2 | 3.86 | 2.43 × 10−2 | myosin, heavy polypeptide 6, cardiac muscle, alpha |
|
| −1.89 | 2.05 × 10−2 | −2.08 | 6.29 × 10−3 | myocilin |
|
| −0.82 | 2.05 × 10−2 | −0.86 | 1.59 × 10−2 | nerve growth factor receptor (TNFR superfamily, member 16) |
|
| −0.85 | 3.58 × 10−2 | −1.56 | 6.29 × 10−3 | NK6 homeobox 1 |
|
| −0.66 | 3.58 × 10−2 | 0.96 | 6.29 × 10−3 | neurogranin |
|
| −0.84 | 2.05 × 10−2 | −2.22 | 6.29 × 10−3 | peripherin |
|
| −1.70 | 2.05 × 10−2 | −3.54 | 6.29 × 10−3 | relaxin 3 |
|
| 0.99 | 2.05 × 10−2 | 2.20 | 6.29 × 10−3 | solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
| −0.85 | 2.05 × 10−2 | −0.82 | 3.74 × 10−2 | smoothened, frizzled class receptor |
|
| 4.61 | 2.05 × 10−2 | 4.58 | 6.29 × 10−3 | TATA-box binding protein associated factor, RNA polymerase I, D |
|
| 0.87 | 4.87 × 10−2 | 1.87 | 6.29 × 10−3 | tryptophan hydroxylase 2 |
|
| 1.73 | 4.87 × 10−2 | 2.10 | 6.29 × 10−3 | vezatin, adherens junctions transmembrane protein |
* Genes, encoding transcription factors.
Metabolic pathways most significantly altered in winners compared to defeated mice.
| Gene Symbol | Mice | Log2 (Fold_Change) Losers/Winners | q_Value | Definition | |
|---|---|---|---|---|---|
| Winners FPKM | Losers FPKM | ||||
|
| |||||
|
| 22.69 | 33.70 | 0.57 | 6.12 × 10−3 | calcium/calmodulin-dependent protein kinase II alpha |
|
| 21.21 | 36.21 | 0.77 | 6.12 × 10−3 | dopa decarboxylase |
|
| 3.97 | 6.68 | 0.75 | 6.12 × 10−3 | FBJ osteosarcoma oncogene |
|
| 1.53 | 9.77 | 2.68 | 6.12 × 10−3 | solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
| 12.78 | 22.60 | 0.82 | 6.12 × 10−3 | tyrosine hydroxylase |
|
| |||||
|
| 79.62 | 118.76 | 0.58 | 6.12 × 10−3 | calcyon neuron-specific vesicular protein |
|
| 22.69 | 33.70 | 0.57 | 6.12 × 10−3 | calcium/calmodulin-dependent protein kinase II alpha |
|
| 21.21 | 36.21 | 0.77 | 6.12 × 10−3 | dopa decarboxylase |
|
| 3.97 | 6.68 | 0.75 | 6.12 × 10−3 | FBJ osteosarcoma oncogene |
|
| 1.53 | 9.77 | 2.68 | 6.12 × 10−3 | solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
| 12.78 | 22.60 | 0.82 | 6.12 × 10−3 | tyrosine hydroxylase |
|
| |||||
|
| 14.22 | 9.93 | −0.52 | 2.68 × 10−2 | calcium channel, voltage-dependent, alpha2/delta subunit 3 |
|
| 14.49 | 21.10 | 0.54 | 6.12 × 10−3 | calcium channel, voltage-dependent, beta 3 subunit |
|
| 22.69 | 33.70 | 0.57 | 6.12 × 10−3 | calcium/calmodulin-dependent protein kinase II alpha |
|
| 73.35 | 50.16 | −0.55 | 1.54 × 10−2 | sodium channel, type IV, beta |
|
| 0.43 | 0.84 | 0.99 | 6.12 × 10−3 | sodium channel, voltage-gated, type V, alpha |
|
| 2.35 | 4.39 | 0.90 | 1.09 × 10−2 | troponin T2, cardiac |
|
| |||||
|
| 253.37 | 123.42 | −1.04 | 6.12 × 10−3 | neurofilament, heavy polypeptide |
|
| 710.19 | 436.14 | −0.70 | 6.12 × 10−3 | neurofilament, light polypeptide |
|
| 557.04 | 277.66 | −1.00 | 6.12 × 10−3 | neurofilament, medium polypeptide |
|
| 26.44 | 10.15 | −1.38 | 6.12 × 10−3 | peripherin |
|
| |||||
|
| 5.38 | 41.27 | 2.94 | 6.12 × 10−3 | neuropilin 1 |
|
| 3.03 | 4.52 | 0.58 | 1.54 × 10−2 | plexin C1 |
|
| 5.26 | 8.44 | 0.68 | 4.25 × 10−2 | sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F |
|
| 8.89 | 13.38 | 0.59 | 6.12 × 10−3 | slit homolog 1 (Drosophila) |
|
| 2.72 | 3.78 | 0.48 | 4.25 × 10−2 | unc-5 netrin receptor D |
|
| |||||
|
| 3.92 | 2.29 | −0.78 | 6.12 × 10−3 | collagen, type XXVII, alpha 1 |
|
| 59.64 | 24.33 | −1.29 | 6.12 × 10−3 | secreted phosphoprotein 1 |
|
| 20.72 | 14.58 | −0.51 | 1.09 × 10−2 | synaptic vesicle glycoprotein 2 b |
|
| 36.92 | 26.11 | −0.50 | 1.09 × 10−2 | synaptic vesicle glycoprotein 2c |
|
| |||||
|
| 21.59 | 11.27 | −0.94 | 6.12 × 10−3 | dopamine beta hydroxylase |
|
| 21.21 | 36.21 | 0.77 | 6.12 × 10−3 | dopa decarboxylase |
|
| 12.78 | 22.60 | 0.82 | 6.12 × 10−3 | tyrosine hydroxylase |
|
| |||||
|
| 21.21 | 36.21 | 0.77 | 6.12 × 10−3 | dopa decarboxylase |
|
| 1.53 | 9.77 | 2.68 | 6.12 × 10−3 | solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
|
| 12.78 | 22.60 | 0.82 | 6.12 × 10−3 | tyrosine hydroxylase |
|
| |||||
|
| 3.63 | 5.58 | 0.62 | 6.12 × 10−3 | calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
| 14.22 | 9.93 | −0.52 | 2.68 × 10−2 | calcium channel, voltage-dependent, alpha2/delta subunit 3 |
|
| 14.49 | 21.10 | 0.54 | 6.12 × 10−3 | calcium channel, voltage-dependent, beta 3 subunit |
|
| 3.97 | 6.68 | 0.75 | 6.12 × 10−3 | FBJ osteosarcoma oncogene |
|
| 16.73 | 9.18 | −0.87 | 6.12 × 10−3 | heat shock protein 1 |
|
| 1.06 | 0.62 | −0.79 | 2.32 × 10−2 | MDS1 and EVI1 complex locus |
Expression of genes that changed the level of transcription in comparisons of Losers vs. Control and Winners vs. Control in different directions and characterized as DEGs when comparing Losers vs. Winners.
| Gene Symbol | Losers/Control | Winners/Control | Losers/Winners | Definition | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls FPKM | Losers FPKM | Log2 (Fold_Change) Losers/Controls | q Value | Controls FPKM | Winners FPKM | Log2 (Fold_Change) Winners/Controls | q Value | Log2 (Fold_Change) Losers/winners | q Value | ||
|
| 52.51 | 143.52 | 1.45 | 5.07 × 10−2 | 53.42 | 8.72 | −2.62 | 2.05 × 10−2 | 4.06 | 6.12 × 10−3 | excision repair cross-complementing rodent repair deficiency, complementation group 2 |
|
| 1.04 | 0.69 | −0.59 | 9.99 × 10−1 | 1.06 | 46.25 | 5.45 | 2.05 × 10−2 | −6.04 | 6.12 × 10−3 | lysyl oxidase-like 2 |
|
| 21.95 | 42.78 | 0.96 | 6.29 × 10−3 | 22.35 | 14.15 | −0.66 | 3.58 × 10−2 | 1.62 | 6.12 × 10−3 | neurogranin |
|
| 0.73 | 2.03 | 1.49 | 1.15 × 10−2 | 0.74 | 0.32 | −1.19 | 6.96 × 10−1 | 2.67 | 6.12 × 10−3 | orthodenticle homeobox 2 |
|
| 1.93 | 6.56 | 1.77 | 7.09 × 10−1 | 1.96 | 0.68 | −1.52 | 9.99 × 10−1 | 3.28 | 6.12 × 10−3 | sine oculis-related homeobox 3 |
|
| 6.44 | 9.72 | 0.59 | 1.07 × 10−1 | 6.56 | 3.44 | −0.93 | 2.05 × 10−2 | 1.52 | 6.12 × 10−3 | transcription factor 7 like 2, T cell specific, HMG box |
*—DEGs encoding transcription factors; Genes associated with: #—behavior/neurological phenotype; ∆—abnormal emotion/affect behavior.
Figure 1(A). Axis maximizing the distances between winning and defeated mice; (B). The distribution of expressed genes along the axis representing the correlation between gene expression and mice coordinates along the partial-least squares discriminant analysis (PLS-DA) Axis 1.
Metabolic pathways that include genes that maximize intergroup differences when comparing winners with defeated mice.
| Term ID | Pathway | Count | Genes | |
|---|---|---|---|---|
| mmu04916 | Melanogenesis | 8 | 8.60 × 10−3 | |
| mmu04020 | Calcium signaling pathway | 11 | 9.76 × 10−3 | |
| mmu04713 | Circadian entrainment | 7 | 2.77 × 10−2 | |
| mmu04141 | Protein processing in endoplasmic reticulum | 9 | 4.39 × 10−2 | |
| mmu04350 | TGF-beta signaling pathway | 6 | 4.95 × 10−2 | |
| mmu04261 | Adrenergic signaling in cardiomyocytes | 8 | 5.00 × 10−2 |
*—Genes, differentially expressed in VTA of winners and defeated mice (according to the Cufflinks/Cuffdiff programs).
Figure 2The relationships between DEGs that make the most significant contribution to the intergroup (winners vs. losers) differences according to the PLS-DA analysis. STRING database utilities were used to identify possible associations between encoded proteins. The genes encoding proteins associated with the nervous system development are shown in red; the genes associated with generation of neurons are shown in blue.
Correlation between expression of the key genes (Nrgn, Camk2a, Ercc2, Otx2, and Six3) and genes related to the dopamine signaling pathway.
|
| |||||
|
|
|
|
|
|
|
|
| 0.722 | 0.920 ** | 0.605 | 0.895 * | 0.902 * |
|
| 0.585 | 0.881 * | 0.518 | 0.885 * | 0.893 * |
|
| 0.517 | 0.696 | 0.202 | 0.527 | 0.537 |
|
| 0.475 | 0.865 * | 0.324 | 0.731 | 0.749 |
|
| |||||
|
|
|
|
|
|
|
|
| 0.991 *** | 0.970 ** | 0.909 * | 0.924 ** | 0.944 ** |
|
| 0.953 ** | 0.965 ** | 0.881 * | 0.917 ** | 0.941 ** |
|
| 0.910 * | 0.789 | 0.747 | 0.651 | 0.703 |
|
| 0.865 * | 0.942 ** | 0.860 * | 0.951 ** | 0.954 ** |
Level of significance (two-tailed test): * <0.05; ** <0.01; *** <0.001.